© 1996 British Society for Rheumatology
research-article |
SURVIVAL FOLLOWING THE ONSET OF SCLERODERMA: RESULTS FROM A RETROSPECTIVE INCEPTION COHORT STUDY OF THE UK PATIENT POPULATION
ARC Epidemiology Research Unit, University of Manchester Stopford Building, Oxford Road, Manchester M13 9PT
*Rheumatology Unit, Royal Free Hospital Pond Street, London NW3 2QG
Correspondence to:
Correspondence to: A. J. Silman, ARC Epidemiology Research Unit, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT.
Sclerodcrma is a multisystem disease which in many populations is reported to have a substantially reduced survival. One problem with many of the published studies is the inclusion of patients with differing lengths of disease at baseline, with the possibility of left censorship bias. The aim was to determine the survival and its predictors in a cohort of scleroderma patients with new onset of disease. All 283 new patients referred to one of the authors (CMB) who had a reported disease onset after 1 January 1982 were studied. Detailed clinical and laboratory information at baseline and at 1 yr were extracted from the structured records. Vital status as at 1 December 1993 was determined using the UK's NHS Central Register. Expected numbers of deaths were obtained by applying local age and sex all-cause mortality rates. In total, there were 1871 person-years of follow-up with crude mortality rates of 3.9 and 2.6%/year, respectively, in males and females. The mortality rate remained approximately constant over the first 10 yr of follow-up. In comparison with expected survival, based on the age distribution of the cohort, there was an overall 4-fold increased mortality rate in this group which was higher in females [standardized mortality ratio (SMR) 4.6, 95% CI 3.2–6.2] than in males (SMR 3.2, 95% CI 1.8–5.0). Analysis of cause-specific mortality showed that 79% of the excess deaths were scleroderma related, but this proportion was substantially lower in males than in females (67% vs 83.9%). These data confirm the increased mortality rate associated with scleroderma, but these rates are lower than those reported from other centres. Females have a higher age-adjusted mortality which is reflected in the different pattern of mortality between the sexes.
KEY WORDS: Scleroderma, Mortality, Survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Chung, E. Krishnan, and E. F. Chakravarty Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample Rheumatology, December 1, 2007; 46(12): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Penn, A.J. Howie, E.J. Kingdon, C.C. Bunn, R.J. Stratton, C.M. Black, A. Burns, and C.P. Denton Scleroderma renal crisis: patient characteristics and long-term outcomes QJM, August 1, 2007; 100(8): 485 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Rigamonti, L M Shand, M Feudjo, C C Bunn, C M Black, C P Denton, and A K Burroughs Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis Gut, March 1, 2006; 55(3): 388 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Volpe, D. Biasi, P. Caramaschi, W. Mantovani, L. M. Bambara, S. Canestrini, M. Ferrari, G. Poli, M. Degan, A. Carletto, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features Rheumatology, March 1, 2006; 45(3): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hesselstrand, R. Ekman, J. Eskilsson, A. Isaksson, A. Scheja, A.-K. Ohlin, and A. Akesson Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001 Rheumatology, March 1, 2005; 44(3): 366 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hachulla and J G Coghlan A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hesselstrand, A. Scheja, G. Q. Shen, A. Wiik, and A. Akesson The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis Rheumatology, April 1, 2003; 42(4): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Morgan, C Knight, M Lunt, C M Black, and A J Silman Predictors of end stage lung disease in a cohort of patients with scleroderma Ann Rheum Dis, February 1, 2003; 62(2): 146 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Simeon, L. Armadans, V. Fonollosa, R. Solans, A. Selva, M. Villar, J. Lima, J. Vaque, and M. Vilardell Mortality and prognostic factors in Spanish patients with systemic sclerosis Rheumatology, January 1, 2003; 42(1): 71 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Young, M. Ho, H. Vosper, J. J. F. Belch, and C. N. A. Palmer Elevated expression of the genes encoding TNF-{alpha} and thromboxane synthase in leucocytes from patients with systemic sclerosis Rheumatology, August 1, 2002; 41(8): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J Geirsson, F A Wollheim, and A Akesson Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale Ann Rheum Dis, December 1, 2001; 60(12): 1117 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G Vlachoyiannopoulos, U. G Dafni, I. Pakas, M. Spyropoulou-Vlachou, C. Stavropoulos-Giokas, and H. M Moutsopoulos Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele Ann Rheum Dis, May 1, 2000; 59(5): 359 - 367. [Abstract] [Full Text]
|
|
|
|
|
|
I. Foeldvari, M. Zhavania, N. Birdi, R. J. Cuttica, S. H. F. de Oliveira, P. B. Dent, R. Elborgh, F. Falcini, G. Ganser, H. Girschick, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey Rheumatology, May 1, 2000; 39(5): 556 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, D. Veale, C. Eastmond, G. Nuki, and J. Belch Macrovascular disease and systemic sclerosis Ann Rheum Dis, January 1, 2000; 59(1): 39 - 43. [Abstract] [Full Text]
|
|
|
|
|
|
R. Hesselstrand, A. Scheja, and A. Åkesson Mortality and causes of death in a Swedish series of systemic sclerosis patients Ann Rheum Dis, November 1, 1998; 57(11): 682 - 686. [Abstract] [Full Text]
|
|